For adults and adolescents (12 to 17 years of age) with PI1

For intravenous use only

Recommended Dose Initial Infusion Rate Maintenance Infusion Rate (if tolerated)
300 to 800 mg/kg every 3 to 4 weeks 0.5 mg/kg/min

(0.005 mL/kg/min) for the first 15 minutes
Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)
  • No apparent differences in efficacy or safety between 3- and 4-week dosing1
  • The dose may be adjusted over time to achieve the desired trough levels and clinical response1
  • ASCENIV™ dose adjustments may be required in patients who fail to maintain trough total IgG concentrations of at least 500 mg/dL with a target of 600 mg/dL. Starting with the second infusion, adjust the dose proportionally, targeting a trough of ≥600 mg/dL, based on the previous trough and the associated dose1

ASCENIV™ is a liquid solution containing 10% IgG (100 mg/mL) for intravenous infusion

  • Available in a single-use, non-latex, tamper-evident 5 g/50 mL vial1
  • Begin with an initial infusion rate of 0.5 mg/kg/min. If there are no adverse reactions, the infusion rate for subsequent infusions can be slowly increased to the maximum rate1
  • Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a slower rate which is comfortable for the patient1
  • Ensure that patients with preexisting renal insufficiency are not volume-depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer ASCENIV™ at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates1